Industry News

• European Commission issues positive decision for approval of Seroquel XR  AstraZeneca announced the European Commission issued a positive decision for the approval of once-daily SEROQUEL XR Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder who had sub-optimal response to antidepressant monotherapy.
  AstraZeneca September 02, 2010  
• New England Journal of Medicine reports Xpert MTB/RIF a faster Tuberculosis test  New England Journal of Medicine reports Xpert MTB/RIF a faster, more Cepheid announced that its Xpert(R) MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance."
  Cepheid September 02, 2010  
• Halozyme begins phase 2 clinical trial with insulin analogs Lispro and Aspart with rHuPH20  Halozyme Therapeutics announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme in combination with the two leading commercially available mealtime analogs: insulin aspart, NovoLog, and insulin lispro, the active ingredient in Humalog.
  Halozyme Therapeutics, Inc. September 02, 2010  
• XOMA regains NASDAQ compliance  XOMA announced that NASDAQ has notified the Company that it regained compliance with the minimum $1.00 per share bid price requirement for continued listing. Accordingly, the Company will continue to be listed on The NASDAQ Global Market.
  XOMA Ltd. September 02, 2010  
• XOMA regains NASDAQ compliance  XOMA announced that NASDAQ has notified the Company that it regained compliance with the minimum $1.00 per share bid price requirement for continued listing. Accordingly, the Company will continue to be listed on The NASDAQ Global Market.
  XOMA Ltd. September 02, 2010  
• Bionovo receives NIH grant to develop drugs for the treatment of female-specific obesity  Bionovo announced that the NIH, National Center for Complementary and Alternative Medicine Small Business Technology Transfer Program, has approved and funded a grant to be shared by Bionovo and Dr. Dale Leitman from the University of California at Berkeley.
  Bionovo, Inc. September 02, 2010  
• Allergan resolves investigation of past sales and marketing practices related to BOTOX(R)  Allergan announced a resolution with the U.S. Department of Justice regarding Allergan's past U.S. sales and marketing practices relating to therapeutic uses of BOTOX. Allergan pled guilty to a single misdemeanor "misbranding" charge covering the period 2000 through 2005 and will pay $375 million.
  Allergan, Inc. September 01, 2010  
• Merck and Cardiome annoumnce BRINAVESS for infusion approved in the European Union  Merck and Cardiome Pharma Corp. announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the rapid conversion of recent onset atrial fibrillation.
  Merck & Co., Inc. September 01, 2010  
• BARDA funds development of new way to treat illness from acute radiation  The HHS Biomedical Advanced Research and Development Authority awarded a $153 million contract to Cellerant Therapeutics of San Carlos, Calif., to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body’s cells.
  U.S. Health & Human Services September 01, 2010  
• U.S. Court of Appeals upholds validity of Lilly's Evista patents through March of 2014  Eli Lilly and Company announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista are valid in the U.S. through March of 2014.
  Eli Lilly and Company September 01, 2010  

   (next 10 articles)